Myelodysplastic Syndrome (MDS)
We recommend
Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia,…
How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
Articles on this topic
Subscribe
Most read on this topic
- How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
- Promising treatment modalities in the therapy of myelodysplastic syndromes
- Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome
- Treatment strategies for myelodysplastic syndrome in 2021
- Myelodysplastický syndrom, refrakterní anemie a O2 sensing
- Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
Journal on this topic
Related topic